Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Cogstate (ASX:CGS) Sells Off 22% on Timing Delay, But the Fundamentals Stay Intact

Cogstate’s H1 Hit Is a Timing Story, Not a Demand Story Cogstate Ltd (ASX:CGS) delivered a business update this morning that reset expectations for its H1 FY26 revenue timing and margin outlook, which triggered a sharp 22% sell-off. The market reacted to near-term revenue being pushed into the back half of the year due to…

ByCharlie YouldenDecember 10, 2025

Immutep (ASX:IMM) Surges on US$369M Global Partnership With Dr. Reddy’s

Immutep Lands Global Deal With Dr. Reddy’s Immutep (ASX:IMM) surged 23% at market open after announcing a new strategic partnership through a collaboration and licensing agreement with Dr Reddys Laboratories, a major global pharmaceutical company based in India. Under the deal, Dr Reddys secures exclusive rights to develop and commercialise Efti across all markets outside…

ByCharlie YouldenDecember 9, 2025

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

On Monday December 22, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others will be demoted. It is important to note from the outset the June and December rebalances only involve the ASX 50, ASX 100 and ASX 200 indices whilst the March and September rebalances also involve…

ByNick SundichDecember 9, 2025

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

TLX Delivers Clinical Progress It’s good to finally see some positive news from Telix Pharmaceuticals (ASX:TLX) after a relatively quiet period, especially following recent market nerves around the FDA slowdown and a few ASX announcement missteps. Today, the company reported an important milestone in its PROSTACT Global Phase 3 trial, confirming that the first patient…

ByCharlie YouldenDecember 8, 2025

Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?

The tables have turned, and shareholders face a key decision as the 10 December deadline approaches. Mayne Pharma (ASX: MYX) has turned the tables on US suitor Cosette Pharmaceuticals, issuing a termination notice alleging "wilful and intentional" breaches of their A$672 million takeover agreement. The Adelaide-based company, which spent much of 2025 fighting Cosette's attempts…

ByUjjwal MaheshwariDecember 5, 2025

Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut

Saluda Medical (ASX:SLD) listed on Friday after raising AU$230 million at AU$2.65 per share, marking a rare bright spot in an otherwise quiet year for ASX biotech debuts. Unlike most life sciences IPOs that arrive with little more than clinical-stage promise, Saluda Medical already generates US$70 million in annual revenue and is targeting US$82 million…

ByUjjwal MaheshwariDecember 4, 2025

Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch Australia's first-in-human head and neck cancer imaging study. The ground-breaking study will recruit 50 patients at the St John of God Healthcare campus in Murdoch and will be led by prominent Perth head and neck cancer surgeon Dr Chady Sader. For investors tracking…

ByUjjwal MaheshwariDecember 4, 2025

Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device

Epiminder (ASX: EPI) made its ASX debut on Monday after raising $125 million at $1.50 per share, giving the company a market capitalisation of approximately $325 million. The Melbourne-based medtech is backed by hearing implant giant Cochlear (ASX: COH), which holds a 36% stake following the listing. For investors, the critical question now is whether…

ByUjjwal MaheshwariDecember 2, 2025

Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates

Paragon Care (ASX: PGC) is betting big on Asia. The healthcare distributor, currently trading near its 52-week lows around $0.29, has struck a $70 million deal to acquire Haju Medical, an Indonesian aesthetics business that sells devices and injectables to dermatologists and cosmetic surgeons. This is the company's second acquisition in just four weeks, signalling…

ByUjjwal MaheshwariDecember 2, 2025

Mayne Pharma Collapses 30% as Treasurer Flags National-Interest Block in Cosette Deal

Mayne Pharma in Freefall: Regulatory Hurdle Threatens $672 m Buy-out Mayne Pharma (ASX: MYX) has suddenly become one of the most talked-about stocks on the ASX after the federal Treasurer raised serious national-interest concerns about its proposed takeover by Cosette Pharmaceuticals. The company that looked like it was on the cusp of being acquired is now…

ByCharlie YouldenOctober 31, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Cogstate (ASX:CGS) Sells Off 22% on Timing Delay, But the Fundamentals Stay Intact

Immutep (ASX:IMM) Surges on US$369M Global Partnership With Dr. Reddy’s

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?

Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut

Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device

Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates

Mayne Pharma Collapses 30% as Treasurer Flags National-Interest Block in Cosette Deal

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here